While blockade of the CSF1/CSF1R pathway has shown promise in reducing immunosuppressive M2-like macrophages (Zhu et al., 2014), recent clinical trials have yielded disappointing outcomes, emphasizing the significance of treatment timing and tumor type. The gene discussed is CSF1R; the disease is neoplasm.